ICC: Use at a dilution of 1/50 - 1/1000. IHC-Fr: Use at an assay dependent dilution. RIA: Use at a concentration of 1 μg/ml. WB: Use at a concentration of 2 μg/ml. Predicted molecular weight: 208.6 kDa. Optimal dilutions/concentrations should be determined by the end user.
GTX12362 detects all isoforms of agrin. This antibody recognizes all N1 isoforms but, consistent with the epitope mapping investigations, fails to see the N4 protein. Furthermore, the antibody will detect the X, Y and Z splice variants.
Preservative: NoneConstituents: 50% Glycerol, PBS, 0.1mM PMSF. pH 7.2
Store as concentrated solution. Centrifuge briefly prior to opening vial. For short-term storage (1-2 weeks), store at 4ºC. For long-term storage, aliquot and store at -20ºC or below. Avoid multiple freeze-thaw cycles.
1 mg/ml (Please refer to the vial label for the specific concentration.)
Recombinant rat agrin, C-terminal construct.
Protein G purified
For laboratory use only. Not for any clinical, therapeutic, or diagnostic use in humans or animals. Not for animal or human consumption.
Agrin , Agr , Agrn
Synaptic basal lamina at the neuromuscular junction.
Agrin is an essential extracellular matrix component which promotes clustering of nicotinic acetylcholine receptors (nAChRs) and other proteins during development at the neuromuscular junction. Agrin, MuSK and Rapsyn are all essential components for AChR aggregation, through an unknown mechanism. The C-terminal region of agrin is released into the medium, interacts with receptors on the muscle surface and induces AChR aggregation. The central region contains two O-linked glycosylation sites and a domain homologous to domain III of laminin. The N-terminal region anchors agrin to the extracellular matrix via other basal membrane components. This region also contains a protease inhibitor domain and glycosaminoglycan attachment sites; increasing the predicted MW from 200kDa to ~600kDa.